ArticleCancer medicine2021
Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Cancer-related mortality among solid organ transplant recipients: systematic review and meta-analysis.Frontiers in transplantation · 2026Pooled it
- The Impact of Chronic Kidney Disease on Oral Health: A Narrative Review.Journal of clinical medicine · 2026Review
- Robot-Assisted Right Hemicolectomy for Ascending Colon Cancer in a Kidney Transplant Recipient: A Case Report.Cureus · 2026Article
- Trends in mortality among patients with malignant neoplasm of kidney in the United States, 1999-2023: a retrospective study.BMC cancer · 2026Article
- Mortality trends of malignant neoplasm of kidney among 5-85+ year-olds in the United States: a retrospective analysis.Frontiers in oncology · 2026Article
- Clinical management of cancer after kidney transplantation.Frontiers in immunology · 2026Review
- ABO-incompatible living-donor kidney transplantation is not associated with post-transplant malignancy: a multicenter retrospective study.Clinical and experimental nephrology · 2026Article
- Incidence and risk of cancer emergence among patients post-kidney transplantation in Japan.Clinical and experimental nephrology · 2025Observational
- Article
- Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant.Frontiers in immunology · 2025Article
- A retrospective study of the incidence of cancer and associated risk factors in kidney transplant patients in a Latin American population between 2007 and 2022.SAGE open medicine · 2025Article
- Observational
- DoesClinical kidney journal · 2024Article
- Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.Clinical and experimental nephrology · 2024Article
- Editorial: Non-immunological care of the kidney transplant recipients.Frontiers in nephrology · 2024Article
- Incidence of Malignancy and Risk Factors Associated with Kidney Transplant Patients.Galen medical journal · 2024Article
- Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.International journal of clinical oncology · 2023Review
- Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.International journal of clinical oncology · 2023Review
- Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis.Translational andrology and urology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplantation is the most promising treatment to improve mortality and life quality in end-stage kidney disease; however, cancer remains a leading cause of death. Several factors including immunosuppressants might be associated with a gradual increase in cumulative cancer incidence after kidney transplantation. Risk factors for cancer and overall and cancer-specific survival were analyzed in 1973 kidney transplant recipients from three study institutions in Japan. The 5-, 10-, 20-, and 30-year overall and cancer-specific survival rates were 93.3%, 88.4%, 78.0%, and 63.6% and 99.4%, 98.0%, 95.3%, and 91.7%, respectively. The overall survival rate was significantly higher and the graft survival rate was significantly lower in recipients without cancer than in those with cancer. Older recipient age, longer dialysis duration before kidney transplantation, and history of transfusion were significant predictors of cancer. Dialysis duration before kidney transplantation was a prognostic factor of overall survival rate. Regarding cancer-specific survival rates, older recipient age and dialysis duration before kidney transplantation were prognostic factors of worse cancer-specific survival rates. The type of immunosuppressant was not associated with an increased cancer rate. Aggressiveness of immunosuppressant regimens or potent immunosuppressants might improve graft survival rate while inducing de novo cancer after kidney transplantation. Older age and longer dialysis duration before kidney transplantation were risk factors of cancer-specific survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.